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Background: To investigate associations between dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2)
expression and survival in T1 high-grade or T2 bladder cancer patients treated with neoadjuvant chemotherapy.
Methods: The cohort under investigation comprised 44 patients who underwent neoadjuvant chemotherapy for pT1
high-grade or pT2N0M0 bladder cancer at our institution between 2002 and 2011. Immunohistochemical analysis was
used to determine expression of DYRK2 in bladder cancer specimens obtained by transurethral resection before
chemotherapy. Relationships between DYRK2 expression and both response to chemotherapy and survival in these
patients were analyzed.
Results: DYRK2 expression was positive in 21 of 44 patients (47.7 %) and negative in 23 patients (52.3 %). In total, 20 of
21 DYRK2-positive cases showed complete response to neoadjuvant chemotherapy, whereas 11 of 23 DYRK2-negative
cases did not show complete response. Sensitivity and specificity were 62.5 % and 91.7 %, respectively (P = 0.0018).
In addition, disease-specific survival rate was significantly higher for DYRK2-positive patients than for DYRK2-negative
patients (P = 0.017). In multivariate analysis, DYRK2 expression level was identified as an independent prognostic factor
for disease-specific survival (P = 0.029). We also showed that DYRK2 mRNA expression was significantly higher in
DYRK2-positive samples by immunohistochemistry than DYRK2-negative samples (P = 0.040).
Conclusions: DYRK2 expression level may predict the efficacy of neoadjuvant chemotherapy for T1 high-grade and T2
bladder cancer.
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Radical cystectomy is widely performed to treat muscle-
invasive bladder cancer. However, radical cystectomy
only results in 5-year survival in about 50 % of patients
[1–5]. To improve these unsatisfactory results, the use
of peri-operative chemotherapy has been explored. More* Correspondence: shun1982@nms.ac.jp
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have been observed in several trials [6–8].
However, some patients with muscle-invasive bladder
cancer do not achieve results even from neoadjuvant
chemotherapy. To optimize survival, selecting patients with
muscle-invasive bladder cancer who are expected to show a
good response to neoadjuvant chemotherapy is important.
Various pathological factors have been reported as prognos-
tic markers of poor survival in patients with bladder cancer,
but are inadequate for predicting survival in bladder cancer
patients. Therefore, molecular markers that better predictarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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vant chemotherapy are sorely needed.
Dual-specificity tyrosine phosphorylation-regulated
kinases (DYRKs) are a subfamily of protein kinases that
catalyze their autophosphorylation on tyrosine residues
and the phosphorylation of serine/threonine residues on
exogenous substrates [9–11]. DYRKs play key roles in the
regulation of cell differentiation, proliferation, and survival
[12, 13]. Specifically, DYRK2 is associated with cancer sur-
vival. DYRK2 phosphorylates p53 at Ser46 during the
apoptotic response to DNA damage, thereby promoting
cellular apoptosis after genotoxic stress [14]. The presence
of DYRK2 may thus predict response to neoadjuvant
chemotherapy that induces DNA damage. This finding led
us to hypothesize that DYRK2 might be a novel marker of
response to neoadjuvant chemotherapy, including cis-
platin, at our institution. The present study therefore ex-
amined the association between DYRK2 expression and
efficacy of neoadjuvant chemotherapy in clinical practice
for patients with T1 high-grade or T2 bladder cancer.
Methods
Patients and samples
The cohort under investigation comprised 44 patients
who underwent neoadjuvant chemotherapy for pT1 high-
grade or pT2N0M0 bladder cancer at our institution
between April 2003 and February 2011. Having been
compiled for research purposes, this group represents
patients for whom pretreatment, archival paraffin-
embedded tissue blocks and data from complete clinical
follow-up were available. Diagnostic work-up included ini-
tial transurethral resection of bladder tumor (TURBT),
pelvic magnetic resonance imaging (MRI), chest and
abdominal computed tomography (CT), and bone scintig-
raphy. Tumors were graded histologically in accordance
with World Health Organization (WHO) classifications
and were staged as per the TNM staging system of the
Union for International Cancer Control (2009). Histo-
logical type was urothelial carcinoma in all cases.
Neoadjuvant intra-arterial chemotherapy was performed
after complete TURBT, only after the patient consented to
therapy based on our recommendation. Written informed
consent was obtained from all patients. Anticancer agents
administered as neoadjuvant chemotherapy consisted of
cisplatin at 100 mg/m2, methotrexate at 30 mg/m2, and
doxorubicin at 20 mg/m2. Our therapeutic protocol
comprised two courses of neoadjuvant chemotherapy.
Following this, a second TURBT was performed to
obtain a biopsy specimen. We assessed the efficacy of
neoadjuvant chemotherapy using the pathological
results of TURBT. Complete response (CR) was defined
as T0 (no evidence of tumor), Ta (noninvasive papillary
tumor), or Tis (tumor at a site distant from the original
tumor), as in RTOG 99–06 [15]. In cases of CR on thesecond TURBT, the bladder was preserved, while advanced
cases and cases with residual invasive bladder tumors were
treated by total cystectomy or systemic chemotherapy [16].
After the second TURBT, cystoscopy and urinary cyto-
logical examinations were performed every 3 months for
2 years, every 6 months from 3–5 years, and annually
thereafter. Chest radiography and pelvic CT were per-
formed every 6 months for 3 years, and annually there-
after. In cases with visible tumors or hyperemic mucosa
in the bladder on cystoscopy or pelvic urinary cytological
findings, transurethral biopsy was performed to detect
disease recurrence.
This study was carried out in accordance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines. Approval of the protocol was obtained from
the Institutional Review Board of Nippon Medical
School, Tokyo, Japan.
Immunohistochemical analysis
DYRK2 expression was determined by immunohisto-
chemical (IHC) staining of paraffin-embedded tissue
sections from TURBT specimens immediately before
neoadjuvant chemotherapy. The 3-μm-thick sections
were deparaffinized, rehydrated using xylene and alco-
hol, and incubated with 0.3 % H2O2 to block
endogenous peroxidase activity. Before immunostaining,
antigen retrieval was performed at 120 °C for 10 min in an
autoclave with citrate buffer (pH 6.0). Staining with a
polyclonal anti-DYRK2 antibody (AP7534a; dilution, 1:50;
Abgent, San Diego, CA, USA) was performed overnight at
4 °C. Histofine Simple Stain Rabbit MAX PO (MULTI;
Nichirei, Tokyo, Japan) was used as the secondary anti-
body in accordance with the manufacturer’s instructions.
Color was developed using diaminobenzidine with 0.01 %
H2O2. Hematoxylin was used as a counterstain. Stained
tumor tissues were evaluated blindly with respect to
clinical patient data. Cytoplasmic staining was considered
positive, and staining intensity was scored as 0, 1, 2, or 3,
corresponding to no staining, weak, moderate, and strong
intensities, respectively (Fig. 1). Percentage scores of cells
showing cytoplasmic staining were also counted (0–
100 %). Total histochemical score (H-score) was calcu-
lated by multiplying the intensity score by the percentage
score (0–300). An H-score higher than the median was
considered positive. Negative controls were incubated
without the primary antibody.
Analysis of real-time quantitative reverse-transcriptase
polymerase chain reaction
Total RNA from formalin-fixed paraffin-embedded
tissues was isolated using an Allprep DNA/RNA kit
(Qiagen, Tokyo, Japan). The quantity and quality of
RNA were evaluated by spectrophotometry. Reverse





Fig. 1 Immunohistochemical staining of paraffin-embedded sections immediately before neoadjuvant chemotherapy with an anti-DYRK2 antibody.
DYRK2 protein expression was localized within the cytoplasm. Magnification × 600. a DYRK2-negative staining pattern (no staining: score 0).
b DYRK2-negative staining pattern (weak: score 1). c DYRK2-positive staining pattern (moderate: score 2). d DYRK2-positive staining pattern
(strong: score 3)
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plied Biosystems, Foster City, CA, USA). Quantitative
gene expression was determined for DYRK2 (Hs007
05109_s1) and 18 s (Hs03928990_g1) using gene-
specific probes (Applied Biosystems) using TaqMan
Fast Advanced Master Mix and the 7900HT Fast
Real-time PCR system (Applied Biosystems). PCR
conditions were: 5 °C for 2 min and 95 °C for 20 s,
followed by 45 cycles at 95 °C for 1 s and 60 °C for
20 s. Data were then quantified using the comparative
Ct method for relative gene expression compared with
18S as an endogenous control.Statistical analysis
Associations between DYRK2 expression and clinico-
pathological factors were analyzed using the Fisher’s
exact test. Disease-specific survival rates were calcu-
lated using the Kaplan–Meier method and differ-
ences in survival among groups were compared
using log-rank testing. We used Cox proportional
hazards regression analysis to assess DYRK2 expres-
sion and sex for disease-specific survival. Differences
in DYRK2 mRNA between DYRK2-positive and
-negative tumors by IHC analysis were determined
using the paired t-test. P-values < 0.05 were consid-
ered statistically significant. All statistical analyses
were performed using SPSS version 21.0 statistical
software (IBM Corp, Armonk, NY, USA).Results
Patient characteristics
Baseline characteristics for all 44 patients are shown in
Table 1. The mean age of patients at first TURBT was
70 years (range, 43–84 years) and only eight patients
were female. Of the 44 patients, 14 (32 %) showed
pT1 high-grade and 30 (68 %) had pT2. Cystectomy
was performed after intra-arterial chemotherapy in four
patients (9.1 %). With a median follow-up of 47 months,
the 5-year survival rate was 82.7 % for all patients. At
the time of analysis, 36 patients (81.8 %) were alive and
8 patients (18.2 %) had died of bladder cancer. Overall
and disease-specific survival were thus similar.Immunohistochemical assessment of DYRK2 expression
DYRK2 was localized in the cytoplasm of bladder tumor
cells. Representative cases for the different staining levels
(0, 1, 2, and 3) are presented in Fig. 1. Median H-score was
10 (range, 0–230). Therefore, tumors with H-score >10
were deemed DYRK2-positive. Twenty-three specimens
(52.3 %) showed low DYRK2 expression, whereas 21 speci-
mens showed high expression (47.7 %).
The relationship between DYRK2 expression and clini-
copathological factors is summarized in Table 1. No
significant association was observed between DYRK2
expression and the following clinicopathological factors:
age, sex, pathological T stage, histological grade, concur-
rent CIS, or lymphovascular invasion (P > 0.05).
Table 1 Clinicopathological factors of bladder cancer and
associations with DYRK2 expression
Patients (%) DYRK2 expression
Negative Positive P
All patients 44 23 21
Age 0.35
<70 years 17 (39 %) 7 11
≥70 years 27 (61 %) 16 10
Sex 0.70
Male 36 (82 %) 18 18
Female 8 (18 %) 5 3
Pathological T stage 0.27
1 14 (32 %) 5 9
2a 20 (46 %) 11 9
2b 10 (23 %) 7 3
Histological grade
Low 3 (7 %) 1 2 0.60
High 41 (93 %) 22 19
Concurrent CIS 0.23
Yes 7 (16 %) 2 5
No 37 (84 %) 21 16
Lymphovascular invasion 1.00
Yes 3 (7 %) 2 1
No 41 (93 %) 21 20
Fig. 2 Kaplan–Meier survival analysis in patients positive and
negative for DYRK2 expression. Differences in disease-specific survival
between subgroups were analyzed by log-rank test. Disease-specific
survival was significantly longer for DYRK2-positive patients than for
DYRK2-negative patients (P = 0.017)
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Overall, 20 of the 21 DYRK2-positive cases showed CR
after neoadjuvant chemotherapy, whereas 11 of the 23
DYRK2-negative cases showed non-CR. The efficacy of
neoadjuvant chemotherapy as determined by DYRK2
expression had a sensitivity of 62.5 % and specificity of
91.7 % (P = 0.0018, Table 2).
DYRK2 expression and survival
Disease-specific survival was significantly longer for
DYRK2-positive patients than for DYRK2-negative
patients (P = 0.017; Fig. 2). In T2 bladder cancer patients
only, DYRK2 expression was associated with increased
disease-specific survival (P = 0.036). In T1 high-grade
bladder cancer patients only, no significant associationTable 2 DYRK2 immunohistochemical staining and clinical





CR complete responsewas observed between DYRK2 expression and disease-
specific survival (P = 0.157).
Multivariate analysis was performed to evaluate the
influence of DYRK2 on disease-specific survival after
adjusting for possible confounding factors. From the
results shown in Table 1, no clinicopathological factors
were significantly correlated with DYRK2. From the
results of the univariate analysis, however, DYRK2 and
sex significantly correlated with disease-specific survival.
Therefore, only DYRK2 and sex were included in the
Cox proportional hazards model. DYRK2 expression
remained statistically significant (P = 0.029), and the haz-
ard ratio (HR) was 11.5 (95 % confidence interval [CI]:
1.29–102; Table 3).
DYRK2 mRNA expression in bladder cancer tissue
DYRK2 mRNA expression was assessed in 39 samples.
We detected levels of DYRK2 mRNA in DYRK2-positive
and DYRK2-negative samples by IHC analysis. Relative
mRNA levels of the DYRK2 gene (DYRK2 per 18S,
mean ± standard deviation) differed significantly between
DYRK2-positive (mRNA 3.82 ± 2.10) and DYRK2-negative
patients (mRNA 2.65 ± 1.23). Paired t-test showed that
mRNA levels were significantly higher in DYRK2-positive
patients than in DYRK2-negative patients (P = 0.040;
Fig. 3).
Discussion
The present study revealed a significant association
between DYRK2 expression and efficacy of neoadjuvant
Table 3 Univariate and multivariate analysis for disease-specific
survival
Disease-specific survival
Univariate analysis Multivariate analysis
Characteristics P HR (95 % CI) P
Age (<70 years vs.
≥70 years)
0.37















0.017 11.5 (1.29-102) 0.029
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patients. High levels of DYRK2 expression was associated
with increased disease-specific survival time in T1 high-
grade and T2 bladder cancer patients treated with neoad-
juvant chemotherapy. In multivariate analysis, DYRK2
expression levels emerged as independent prognostic
markers of survival. DYRK2 may therefore predict prog-
nosis independent of common prognostic factors, such
as clinical T stage and histological grade. Moreover, we
showed that DYRK2 mRNA expression was significantlyFig. 3 Relative levels of DYRK2 mRNA in DYRK2-positive and -negative
cases by IHC analysis. DYRK2 mRNA levels were significantly higher in
DYRK2-positive patients than in DYRK2-negative patients (P = 0.040)higher in DYRK2-positive samples by IHC than DYRK2-
negative samples.
DYRK2 is an important factor in cellular apoptosis
after genotoxic stress. Taira et al. reported that knock
down of DYRK2 function attenuates the apoptosis elic-
ited by DNA damage induced by doxorubicin in vitro
[14]. Yamashita et al. reported that DYRK2 may predict
progression-free survival in patients with recurrent non-
small-cell lung cancer treated using platinum-based
chemotherapy [17]. DYRK2 can thus predict response to
different chemotherapies, including doxorubicin and
cisplatin. As our regimen includes both cisplatin and
doxorubicin, DYRK2 may therefore be a useful marker
of sensitivity to neoadjuvant chemotherapy at our insti-
tution. Furthermore, one of the most popular neoadju-
vant chemotherapy regimens includes methotrexate,
vinblastine, doxorubicin, and cisplatin (M-VAC), while
another popular neoadjuvant chemotherapy regimen
consists of gemcitabine and cisplatin (GC). Thus,
DYRK2 may predict response to M-VAC and GC.
Therefore, trials with M-VAC and GC are needed to
confirm this hypothesis.
Few genetic markers have been confirmed to predict
survival in bladder cancer patients treated with chemo-
therapy. Bellmunt et al. reported that excision repair
cross-complementing 1 (ERCC1) gene expression may
predict survival in patients with bladder cancer treated
with platinum-based therapy [18]. Moreover, Font et al.
reported that bladder cancer susceptibility 1 (BRCA1)
gene expression may predict the efficacy of cisplatin-based
neoadjuvant chemotherapy [19]. Finally, Hoffmann et al.
reported that high multidrug resistance 1 (MDR1) gene
expression was associated with inferior outcomes after
cisplatin-based adjuvant chemotherapy for locally
advanced bladder cancer [20]. We have also previously re-
ported that Snail expression may predict poor outcomes
in bladder cancer patients treated with neoadjuvant
chemotherapy [21]. Thus, Use of ERCC1, MDR1, BRCA1,
and Snail in combination with DYRK2 may further
improve the accuracy of predicting survival in bladder
cancer patients treated with neoadjuvant chemotherapy.
We have previously reported that CYFRA 21–1 may
be a useful marker for monitoring neoadjuvant chemo-
therapy [16]. However, this marker cannot predict the
efficacy of neoadjuvant chemotherapy prior to adminis-
tration. The results of the present study indicate that
DYRK2 can help identify patients with T1 high-grade
and T2 bladder cancer that will respond to neoadjuvant
chemotherapy. Therefore, a selective approach using this
information could result in patients with high DYRK2
expression receiving neoadjuvant chemotherapy, while
those with low DYRK2 expression would undergo
radical cystectomy. Prospective studies applying this
approach are needed in the future.
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was associated with increased disease-specific survival
time (P = 0.036). However, no significant association was
observed between DYRK2 expression and disease-
specific survival in only T1 high-grade bladder cancer
patients (P = 0.157). However, a trend toward longer
disease-specific survival was observed. Further studies
with a large cohort of T1 high-grade bladder cancer pa-
tients are warranted to confirm this result.
One limitation of the present study is that we have not
shown a direct role of DYRK2 in bladder cancer. However,
our DYRK2 staining results with clinical samples suggest
that the abundance of DYRK2 is associated with the
response to neoadjuvant chemotherapy. Other limitations
of this study include that the sample size for DYRK2
immunohistochemical analysis was very small, the study
was retrospective, and our regimen does not represent
standard chemotherapy. More detailed studies are needed
to address these limitations.
Conclusions
Although the sample size of this study was small, our
results indicate that DYRK2 might represent a new
molecular marker for predicting the efficacy of neoad-
juvant chemotherapy in T1 high-grade and T2 blad-
der cancer. Further careful study is needed to confirm
our preliminary results.
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